Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

  • Technology appraisal guidance
  • TA375
  • Published: 

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment group report

Assessment group report impact of decision support unit report health assessment questionnaire (HAQ) progression on clinical and cost effectiveness

This page was last updated: 18 March 2015